Sign inJoin waitlistJoin the waitlist

Alexander E Perl

Associate Professor of Medicine · Hospital of the University of Pennsylvania

Credentials: · · · · ·

History

Hospital of the University of Pennsylvania
Present

Research

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
Cancer Cell · 2010 · 1,679 citations
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · First of 31 authors · 1,078 citations
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Nature · 2012 · 623 citations

ML
Mark Levis
42 papers
Selina Luger
39 papers
Martin Carroll
31 papers
Alison Loren
28 papers
David Porter
25 papers
Noelle Frey
22 papers
Catherine Smith
21 papers
Edward Stadtmauer
21 papers
Elizabeth Hexner
20 papers
Jessica Altman
18 papers
Saar Gill
16 papers
Eunice Wang
15 papers

Grants

mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
National Cancer Institute · K23
Contact PI · $861.8K · University of Pennsylvania
2010–2015

Clinical trials

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Principal investigator · Completed · Phase 1, Phase 2
Daiichi Sankyo
2011–2018
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Site PI · Recruiting · Phase 1
Uma Borate
2024–2027
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Site PI · Recruiting · Phase 1, Phase 2
Syndax Pharmaceuticals
2019–2027